467 results about "Chronic renal failure" patented technology

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.

An artificial liver system for treating liver failure includes a reservoir to provide albumin-containing dialysis fluid to the patient's peritoneum, an implantable device including a pump to pump the fluid from the peritoneum to the bladder via respective catheters, control circuitry, battery and transceiver; a charging and communication system configured to periodically charge the battery and communicate with the implantable device to retrieve data reflective of the patient's health; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable device and charging and communication system. The monitoring and control software allows a treating physician to remotely adjust the volume, time, and frequency with which fluid is pumped from the peritoneal cavity to the bladder based on the data reflective of the patient's health.

The invention provides a method for determining a dose and dosing schedule, and making dose adjustments of patients taking PBA prodrugs as nitrogen scavengers to treat nitrogen retention states, including ammonia accumulation disorders as well as chronic renal failure, by measuring urinary excretion of phenylacetylglutamine and / or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered waste nitrogen scavenging drug, and to monitoring patients receiving such drugs.

The present invention provides a polysulfone type hollow fiber membrane which is reliable in safety and stability of performance and is easily incorporated into a module, and thus can be suitably used in a highly water permeable blood purifier for use in a therapy of chronic renal failure. The present invention relates to a polysulfone type selectively permeable hollow fiber membrane comprising a polysulfone type resin and a hydrophilic polymer as main components, and characterized in that (A) the content of the hydrophilic polymer in the uppermost layer of a surface of the polysulfone type hollow fiber membrane on the blood-contacting side is at least 1.1 times larger than the content of the hydrophilic polymer in the proximate layer of the surface on the blood-contacting side, and (B) the content of the hydrophilic polymer in the uppermost layer of the other surface of the polysulfone type hollow fiber membrane, i.e., the reverse side of the surface on the blood-contacting side, is at least 1.1 times larger than the content of the hydrophilic polymer in the uppermost layer of the surface on the blood-contacting side.

The invention discloses a novel traditional Chinese medicine composition for treating the symptoms of renal calculus and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw materials of medicines: scaly anteater, rhizoma sparganii, rhizoma zedoariae, sweetgum fruit, immature bitter orange, Chinese eaglewood, dalbergia wood, tangerine peel, TurmericRoot-tuber, chicken's gizzard-membrane, radix notoginseng, rhizoma ligustici wallichii, red peony root, peach kernel, safflower, logwood, mastic, myrrh, draconis sanguis, Chinese polyphaga, rhizoma cyperi, tuckahoe, radix puerariae, rhizoma alismatis, manchurian dutchmanspipe, japanese fern spore, semen lepidii, talcum, rosa banksiae, green tangerine peel, toosendan fruit, areca peel, dahurian angelica root, rhizoma atractylodis, schisandra fruit and motherwort. The traditional Chinese medicine composition can be prepared into any common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can obviously improve the symptoms of the metabolic balance maladjustment of colloids and crystals, infection, nutrition metabolic disturbance, the calculus and the urine stasis of the urinary system, lumbago, renal colic, bloody urine and the like in the body of a patient with the symptoms of the renal calculus, can improve the symptoms of gout, diabetes, hypertension, acute pyelonephritis, chronic renal failure, uremia and the like caused by the symptoms of the renal calculus and has definite clinical curative effect, obvious curative effect and quick acting. Because of basically adopting medicine-food homologous medicines specified by the dispensatory of China for combination, the traditional Chinese medicine composition has the advantages of low cost, no toxic or side effect basically and the like.

The present invention provides a highly water permeable hollow fiber membrane type blood purifier for medical use, which is excellent in safety and module-assembling ease and which has a high water permeability suitable for use in therapy of chronic renal failure.The present invention relates to a highly water-permeable hollow fiber type blood purifier comprising hydrophobic polymer hollow fiber membranes each of which contains a hydrophilic polymer, characterized in that the amount of the hydrophilic polymer eluted from the hollow fiber membrane is 10 ppm or less; in that the ratio of the hydrophilic polymer in the outer surface of the hollow fiber membrane is 25 to 50 mass %; in that the burst pressure of the hollow fiber membrane is 0.5 MPa or higher; and in that the coefficient of water permeability of the blood purifier is 150 ml / m2 / hr. / mmHg or higher.

The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising a phosphate binder and another pharmaceutically active ingredient. The other pharmaceutically active ingredient is selected from a group consisting of antihypertensives, calcitrol, vitamin D analogues, lipid restriction products, potassium salts, treatments for anemia and alkalization compounds.

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and / or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

The invention provides compositions for preventing chronic feline renal failure comprising from about 28 to about 35% protein and compositions for treating chronic renal failure in felines comprising from about 28 to about 30%, wherein the protein comprises at least about 75% vegetable protein and methods for using such compositions to prevent or treat chronic feline renal failure. The invention also provides methods for preparing the compositions, articles of manufacture comprising the compositions, and means for communicating information about the compositions, methods, and articles of manufacture.